49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02021513 (ClinicalTrials.gov)	January 2012	13/12/2013	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Dietary Supplement: Fish Oil;Dietary Supplement: Olive Oil	University of Texas Southwestern Medical Center	NULL	Completed	18 Years	64 Years	Both	50	Phase 2	United States
2	NCT00828178 (ClinicalTrials.gov)	February 2009	22/1/2009	Efficacy of Fish Oil in Lupus Patients	A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.	Systemic Lupus Erythematosus	Drug: Omega-3;Device: flow-mediated dilation of the brachial artery;Other: corn starch	Michelle Petri M.D.,MPH	NULL	Completed	18 Years	N/A	All	106	Phase 4	United States
3	EUCTR2004-004404-21-GB (EUCTR)	10/12/2004	17/02/2005	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Systemic Lupus Erythematosus	Trade Name: Omacor Product Name: Omacor INN or Proposed INN: Eicosapentaenoic acid INN or Proposed INN: Docosahexaenoic acid INN or Proposed INN: alpha-tocopherol	GreenPark Healthcare Trust	Queens University Belfast	Not Recruiting			Female: yes Male: yes	60	Phase 4	United Kingdom